[HTML][HTML] Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R de Haan, D Pluim, B van Triest… - Radiotherapy and …, 2018 - Elsevier
Background PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R Haan, D Pluim, B Triest, M Heuvel… - Radiotherapy and …, 2018 - inis.iaea.org
[en] PARP inhibitors are currently evaluated in combination with radiotherapy and/or
chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.
R de Haan, D Pluim, B van Triest… - … Oncology: Journal of …, 2017 - europepmc.org
Background PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
[PDF][PDF] Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R de Haan, D Pluim, B van Triest… - Radiotherapy and …, 2018 - academia.edu
abstract Background: PARP inhibitors are currently evaluated in combination with
radiotherapy and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low …
radiotherapy and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low …
[引用][C] Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R Haan, D Pluim, B Triest, M Heuvel, H Peulen, D Berlo… - 2018 - repository.ubn.ru.nl
BACKGROUND: PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R de Haan, D Pluim, B van Triest… - … : journal of the …, 2018 - pubmed.ncbi.nlm.nih.gov
Background PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
[引用][C] Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R de Haan, D Pluim, B van Triest… - Radiotherapy and …, 2018 - cir.nii.ac.jp
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for
radiotherapy and chemotherapy combination trials | CiNii Research CiNii 国立情報学研究所 …
radiotherapy and chemotherapy combination trials | CiNii Research CiNii 国立情報学研究所 …
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R de Haan, D Pluim, B van Triest… - Radiotherapy and …, 2018 - thegreenjournal.com
Background PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …